Ranitidine does not increase risk of Gastric Cancer, finds study
Gastric cancer is one of the most common malignancies worldwide, with a significant death rate, particularly in East Asia. N-nitrosodimethylamine (NMDA), which is possibly carcinogenic, is found in several ranitidine products. Many other studies showed that NDMA-contaminated ranitidine could possibly increase the risk of cancer.
A recent study by south Korean researchers found out that the intake of ranitidine created no significant difference associated with increased risk of developing gastric cancer. They published the findings online in Journal of Healthcare on 06 August 2021.
This study used a 1:1 propensity score matching based on sociodemographic. A total of 40,887 people were included in the study under control, other histamine-2 blockers, and ranitidine groups, and 906 of them got stomach cancer during the follow-up period.
During the follow-up period, stomach cancer events were studied using the survival analysis, log-rank test, and Cox proportional hazards regression models to estimate incidence, survival rate, and hazard ratio.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.